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The antibiotic susceptibility rates of 363 clinical Bacteroides fragilis group isolates collected from 17 centers in Argentina during
the period from 2006 to 2009 were as follows: piperacillin-tazobactam, 99%; ampicillin-sulbactam, 92%; cefoxitin, 72%; tigecy-
cline, 100%; moxifloxacin, 91%; and clindamycin, 52%. Nometronidazole resistance was detected in these isolates during this
time period. Resistance to imipenem, doripenem, and ertapenem was observed in 1.1%, 1.6%, and 2.3% of B. fragilis group
strains, respectively. B. fragilis species showed a resistance profile of 1.5% to imipenem, 1.9% to doripenem, and 2.4% to erta-
penem. This is the first report of carbapenem resistance in Argentina. The cfiA gene was present in 8 out of 23 isolates, all of them
belonging to the B. fragilis species and displaying reduced susceptibility or resistance to carbapenems (MICs> 4g/ml). Three
out of eight cfiA-positive isolates were fully resistant to carbapenems, while 5 out of 8 isolates showed low-level resistance (MICs,
4 to 8g/ml). The inhibition by EDTA was a good predictor of the presence of metallo--lactamases in the fully resistant B. fra-
gilis strains, but discrepant results were observed for low-level resistant isolates. B. fragiliswas more susceptible to antimicro-
bial agents than other Bacteroides species. Bacteroides vulgatus species was the most resistant to ampicillin-sulbactam and
piperacillin-tazobactam, and B. thetaiotaomicron/ovatus strains showed the highest level of resistance to carbapenems, with an
unknown resistance mechanism. B. vulgatus and the uncommon non-Bacteroides fragilis species were the most resistant to
moxifloxacin, showing an overall resistance rate of 15.1%.
The increasing resistance to antimicrobial agents among anaer-obic bacteria has become a global problem in the past 2 de-
cades, particularly within the species that make up the Bacteroides
fragilis group, the most frequently isolated species in clinical in-
fections, in which resistance to metronidazole, carbapenems, and
-lactam–-lactamase inhibitor combinations has been reported
(14–16, 29).
Antimicrobial susceptibility testing has been recommended
only in particular clinical situations and microorganisms (6). An-
timicrobial resistance rates vary in different countries and also
among the different medical centers within the same country (2,
15, 20). Therefore, both periodic local and national susceptibility
studies and the evaluation of new therapeutic agents are necessary
to provide data for an appropriate empirical antimicrobial ther-
apy (18).
In Argentina, the Subcomisión de Bacterias Anaerobias de la
Asociación Argentina de Microbiología (SADEBAC-AAM) con-
ducts regular monitoring and surveillance of these bacteria. The
results of the first national survey of antibiotic susceptibility in the
B. fragilis group are reported here.
(This study was presented in part at the 50th Interscience Con-
ference on Antimicrobial Agents and Chemotherapy in Boston,
MA, September 2010.)
MATERIALS AND METHODS
Bacterial isolates. Between 2006 and 2009, a total of 363 nonduplicate
clinical isolates belonging to the B. fragilis group were collected from 17
centers in Argentina. The isolates collected from centers in Ciudad Au-
tónoma de Buenos Aires, Argentina, were from the Hospital General de
Agudos Dr. E. Tornú (77 isolates), Hospital Nacional de Pediatría Prof.
Dr. J. P. Garrahan (70 isolates), Hospital Alemán (69 isolates), Instituto de
Investigaciones Médicas Alfredo Lanari-UBA (22 isolates), Hospital de
Infecciosas F. J. Muñiz (22 isolates), Sanatorio Mitre (7 isolates), Hospital
Dr. P. Piñero (5 isolates), and Sanatorio Mater Dei (2 isolates). In Cór-
doba, the isolates were from Clínica Reina Fabiola (25 isolates), Hospital
Nacional de Clínicas (14 isolates), and Clínica Privada de Río Cuarto (2
isolates). Twenty-one isolates were from the Hospital Dr. J. C. Perrando,
Resistencia, in Chaco. Ten isolates were from the Hospital Provincial de
Neuquén in Neuquén (10 isolates), and nine isolates were from the HIGA
Dr. A Piñero, Junin, in Buenos Aires Province. Two isolates were from the
Hospital Eva Perón in San Martín, five isolates were from the Clínica
Regional Privada, San Genaro, in Santa Fe, and one isolate was from the
Hospital Central Mendoza in Mendoza.
The isolates were recovered from the abdomen (58%), genital tract
(13%), blood (12%), skin and soft tissues (8.5%), as well as from other
body sites (8%).
The species distribution of the isolates was as follows. A total of 198
isolates were Bacteroides fragilis, 69 were Bacteroides thetaiotaomicron/
ovatus, 30 were Bacteroides caccae, and 27 were Bacteroides vulgatus.
Thirty-nine isolates were less frequently isolated species. Of the 39 iso-
lates, 7 were Parabacteroides (Bacteroides) distasonis, 7 were Bacteroides
Received 2 September 2011 Returned for modification 2 October 2011
Accepted 23 December 2011
Published ahead of print 9 January 2012
Address correspondence to Liliana Fernández-Canigia, lfcanigia@labdl.com.ar.
Copyright © 2012, American Society for Microbiology. All Rights Reserved.
doi:10.1128/AAC.05622-11
0066-4804/12/$12.00 Antimicrobial Agents and Chemotherapy p. 1309–1314 aac.asm.org 1309
uniformis, 7 were Bacteroides stercoris, and 2 were Bacteroides merdae, and
16 isolates of the Bacteroides fragilis group could not be fully identified to
the species level (Bacteroides spp.). The isolates were stored at 70°C in
glycerol broth and subcultured onto sheep blood brucella agar for further
testing.
Antimicrobial agents. Standard powders of ampicillin, sulbactam,
piperacillin, tazobactam, cefoxitin, imipenem, clindamycin, metronida-
zole, and moxifloxacin antibiotics were kindly supplied by INEI-ANLIS
Dr. Carlos G. Malbrán, Argentina. Ertapenem was provided by Merck &
Co, West Point, PA. Doripenem was provided by Janssen-Cilag, Argen-
tina, and tigecycline was provided by Wyeth Pharmaceutical, Argentina.
Antimicrobial susceptibility testing. MICs were determined accord-
ing to the reference agar dilution method of the Clinical and Laboratory
Standards Institute (CLSI Document M11-A7) (6) with brucella agar sup-
plemented with 5 g/ml hemin, 1 g/ml vitamin K, and 5% laked sheep
blood. Agar dilution test plates were inoculated with approximately 105
CFU/spot using a Steers multipoint replicator and incubated at 37°C for
48 h in an anaerobic chamber.
The MIC was defined as the lowest concentration of an antimicrobial
agent that will markedly reduce growth occurring on the test plate com-
pared with the anaerobic control plate. Reference strains B. fragilis ATCC
25285 andB. thetaiotaomicronATCC 29741 were used as controls. Results
were recorded only when the MICs corresponding to the control organ-
isms were within the range specified by the CLSI. The breakpoints recom-
mended by the CLSI in CLSI Document M11-A7 (6) were used for most
antibiotics. The breakpoints established by the CLSI for carbapenems
(imipenem and ertapenem) were used for doripenem, and the break-
points recommended by the Food and Drug Administration (FDA) were
used for tigecycline, as there are no published susceptibility criteria rec-
ommendations for this drug (Tygacil package insert; Wyeth Pharmaceu-
ticals). In this study, those isolates displaying carbapenem MICs of 4
g/ml (susceptible) or 8 g/ml (intermediate) were considered to have
decreased susceptibility.
Phenotypic screening for MBLs. Inhibition of metallo--lactamases
(MBLs) by EDTA was evaluated in those isolates that displayed decreased
susceptibility or resistance to carbapenems. A reduction of at least 3 dilu-
tions of the MIC of imipenem in the presence of 0.4 mM EDTA with
respect to the MIC of imipenem alone was considered positive.
Detection of the cfiA gene. PCR amplification for detection of the cfiA
gene was performed in those isolates that displayed resistance or de-
creased susceptibility to carbapenems, using the following primers (5=-3=)
described by Kato et al. (13): GBI-1 (CCCAACTCTCGGACAAAAGTG)
and GBI-2 (AGTGAATCGGTGAATCCATG). Total DNA was obtained
by the boiling method. PCR amplification was run for 30 cycles, with 1
cycle consisting of 1 min at 95°C and 1 min at 57°C. Twenty-two isolates
with carbapenem MICs of2 g/ml were also included.
RESULTS
Antimicrobial susceptibilities of all isolates expressed as MIC
range, MIC50, MIC90, and percentage of susceptibility are summa-
rized in Table 1.
The overall susceptibility rates to -lactams were as follows:
imipenem, 99%; piperacillin-tazobactam, 99%; doripenem, 98%;
ertapenem, 96%; ampicillin-sulbactam 92%; and cefoxitin, 72%.
The susceptibility profiles for the other antibiotics were as follows:
metronidazole, 100%; tigecycline, 100%; moxifloxacin, 91%; and
clindamycin, 52%.
B. fragilis was the most susceptible species with respect to the
majority of the agents tested and showed the highest rates of sus-
ceptibility to ampicillin-sulbactam, cefoxitin, and clindamycin. B.
vulgatus remained susceptible to carbapenems, despite showing
the lowest rates of susceptibility to -lactam–-lactamase inhibi-
tor combinations.
Emergence of resistance to carbapenems and piperacillin-
tazobactam was observed in this study. ForB. fragilis isolates, non-
susceptible rates (including resistant and intermediate strains) to
imipenem, doripenem, and ertapenem were 1.5%, 2.5% and 4%,
respectively, and 0.6%, 2%, and 4.8% for other species of the B.
fragilis group, with B. thetaiotaomicron/ovatus being the most re-
sistant.
Among the resistant isolates, threeB. fragilis isolates and oneB.
thetaiotaomicron/ovatus isolate recovered from blood, bone, peri-
cardial fluid, and abdominal fluid sources showed carbapenem
MICs of16 g/ml.
Correspondence of the phenotypic screening of the MBLs and
genotypic detection of the cfiA gene for all the isolates with de-
creased susceptibility or resistance to carbapenems are shown in
Table 2. The cfiA gene was present in 8 out of 23 isolates, all cor-
responding to the B. fragilis species. Three out of eight cfiA-
positive isolates were resistant to carbapenems and showed inhi-
bition by EDTA. The other five isolates showed decreased
susceptibility to ertapenem and doripenem, and only three strains
scored positive in the phenotypic screening. The cfiA gene was not
detected in any other species of the group, not even in
carbapenem-resistant B. thetaiotaomicron/ovatus. Moreover, the
cfiA gene was not detected in the 22 isolates with carbapenem
MICs of2 g/ml.
The overall susceptibility rate to moxifloxacin was 91%.
Nevertheless, isolates from the uncommon species [Parabacte-
roides (Bacteroides) distasonis, Bacteroides uniformis, Bacte-
roides stercoris, Bacteroides merdae, and Bacteroides spp.] and B.
vulgatus showed the highest moxifloxacin resistance rates, up
to 15.4% and 14.8%, respectively, doubling the rates observed
in the other species.
No metronidazole- or tigecycline-resistant isolates were ob-
served. However, tigecycline MIC90 values among the different
species ranged between 0.125 and 1 g/ml, below the FDA break-
point. Clindamycin showed the lowest activity among all the an-
tibiotics tested, ranging from 42% for B. thetaiotaomicron/ovatus
to 74.7% for B. fragilis species.
Slight variations were observed in the antimicrobial activity
profiles of B. fragilis species according to the source of isolate
(Table 3). However, for skin and soft tissue isolates, cefoxitin dis-
played better activity, while clindamycin and moxifloxacin were
the least active. Similarly, non-B. fragilis species recovered from
skin and soft tissues showed higher resistance to clindamycin,
moxifloxacin, and also cefoxitin (Table 3).
DISCUSSION
As reported previously elsewhere in the world, variability in the
resistance patterns among the species of the B. fragilis group and
the emergence of resistance to some of the most active -lactams
was observed (2, 8, 12, 16, 17, 27).
In this study, the ampicillin-sulbactam susceptibility rates ofB.
fragilis and non-B. fragilis species were 97% and 85%, respectively.
No increase in the resistance to ampicillin-sulbactam has been
observed compared with previous studies conducted in Argen-
tina, so the combination of these two drugs remains a good ther-
apeutic option for anaerobic bacterial infections (8, 15).
Although carbapenems constitute the most active -lactams
against these microorganisms, the emergence of resistance to
carbapenems and also to piperacillin-tazobactam in Argentina
is reported here. Imipenem resistance due to metallo--
lactamases has been reported since 1986 (7); however, it re-
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TABLE 1 In vitro activity of 10 antimicrobial agents against 363 isolates of the Bacteroides fragilis group
Organism (no. of isolates) and
antimicrobial agent(s)
MIC (g/ml) % of isolates with the indicated susceptibility:
Range 50% 90% Susceptible Intermediate Resistant
Bacteroides fragilis (198)
Ampicillin-sulbactam 0.125–128 1 8 97.0 1.5 1.5
Piperacillin-tazobactam 0.03–512 0.25 2 98.5 0.0 1.5
Cefoxitin 1–256 16 32 82.8 11.1 6.1
Ertapenem (126) 0.06–64 0.25 4 96.0 1.6 2.4
Imipenem 0.015–64 0.125 0.5 98.5 0.0 1.5
Doripenem (159) 0.03–64 0.25 1 97.5 0.6 1.9
Clindamycin 0.125–256 1 256 74.7 2.5 22.7
Metronidazole 0.06–4 0.5 1 100.0 0.0 0.0
Moxifloxacin 0.06–64 0.5 2 89.9 2.0 8.1
Tigecycline 0.03–4 0.125 1 100 0.0 0.0
Bacteroides thetaiotaomicron/ovatus (69)
Ampicillin-sulbactam 0.5–32 0.5 1 87.0 8.7 4.3
Piperacillin-tazobactam 0.03–64 0.03 4 98.6 1.4 0.0
Cefoxitin 4–128 4 32 49.3 27.5 23.2
Ertapenem (49) 0.125–64 0.12 1 89.8 4.1 4.1
Imipenem 0.015–16 0.015 0.125 98.6 0.0 1.4
Doripenem (58) 0.125–64 0.125 0.25 96.6 0.0 3.4
Clindamycin 0.125–256 0.125 4 42.0 18.8 39.1
Metronidazole 0.06–2 0.06 0.5 100.0 0.0 0.0
Moxifloxacin 0.125–64 0.125 1 89.9 2.9 7.2
Tigecycline 0.03–2 0.03 0.125 100.0 0.0 0.0
Bacteroides caccae (30)
Ampicillin-sulbactam 0.5–16 1 4 90 10 0
Piperacillin-tazobactam 0.03–8 0.25 4 100 0 0
Cefoxitin 4–128 16 64 63.3 16.7 20
Ertapenem (19) 0.125–8 0.5 4 94.7 5.3 0
Imipenem 0.015–2 0.125 0.5 100 0 0
Doripenem (25) 0.125–8 0.25 1 96 4 0
Clindamycin 0.125–256 1 256 63.3 10 26.7
Metronidazole 0.06–4 0.5 1 100 0 0
Moxifloxacin 0.125–16 0.5 4 86.7 6.7 6.7
Tigecycline 0.03–4 0.5 1 100.0 0 0.0
Bacteroides vulgatus (27)
Ampicillin-sulbactam 0.125–128 4 16 74.1 18.5 7.4
Piperacillin-tazobactam 0.25–512 2 8 96.3 0.0 3.7
Cefoxitin 0.5–128 8 32 81.5 7.4 11.1
Ertapenem (24) 0.125–2 0.5 1 100.0 0.0 0.0
Imipenem 0.015–4 0.25 1 100.0 0.0 0.0
Doripenem 0.06–1 0.25 0.5 100.0 0.0 0.0
Clindamycin 0.125–256 0.5 256 66.7 3.7 29.6
Metronidazole 0.25–4 0.5 1 100.0 0.0 0.0
Moxifloxacin 0.06–128 1 8 81.5 3.7 14.8
Tigecycline 0.03–2 0.06 0.5 100.0 0.0 0.0
Uncommon B. fragilis group species (39)a
Ampicillin-sulbactam 0.125–32 2 16 87.2 10.3 2.6
Piperacillin-tazobactam 0.03–64 1 8 97.4 2.6 0.0
Cefoxitin 4–128 16 64 61.5 20.5 17.9
Ertapenem (34) 0.06–16 0.5 2 97.1 0.0 2.9
Imipenem 0.03–4 0.25 0.5 100.0 0.0 0.0
Doripenem (37) 0.125–4 0.25 1 100.0 0.0 0.0
Clindamycin 0.125–256 2 256 51.3 7.7 41.0
Metronidazole 0.06–4 0.5 2 100.0 0.0 0.0
Moxifloxacin 0.03–64 1 16 79.5 5.1 15.4
Tigecycline 0.03–4 0.125 1 100.0 0.0 0.0
a The 39 uncommon isolates of the B. fragilis group species were found to belong to the following species: Parabacteroides (Bacteroides) distasonis, 7 isolates; Bacteroides uniformis, 7
isolates; Bacteroides stercoris, 7 isolates; Bacteroides merdae, 2 isolates; and Bacteroides spp., 16 isolates.
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mains infrequent in the United States and Europe, ranging
from 0.4% to 1.5%, similar to what was observed in this study
(2, 17, 25, 26, 28).
The production of metallo--lactamase (5) CfiA was reported
to be responsible for resistance to carbapenems in B. fragilis as
early as 1990 (1, 23). The inhibition by EDTA was a very good
predictor for the presence of metallo--lactamases in the highly
resistantB. fragilis strains, but discrepant results were observed for
strains with decreased susceptibility. Phenotypic detection could
be improved using ertapenem instead of imipenem, especially in
TABLE 2 Phenotypic and genotypic characterization of MBLs in carbapenem-resistant isolates and isolates with decreased susceptibility
Organism(s) Center
MIC (g/ml)a
EDTA inhibition cfiA geneERT IMI IMIEDTA DOR
B. fragilis 2 64 64 0.015 64  
1 64 32 0.125 64  
1 32 32 0.06 32  
1 8 4 0.015 4  
3 8 0.5 0.125 4  
1 4 2 0.015 2  
1 4 1 0.125 4  
1 4 1 0.125 4  
2 4 0.5 0.125 4  
1 4 0.5 0.125 1  
2 4 0.5 0.125 1  
5 4 0.25 0.03 8  
6 4 0.06 0.015 4  
8 4 0.25 0.03 2  
B. caccae 1 8 2 0.125 8  
4 4 0.5 0.125 1  
3 4 0.5 0.015 0.5  
B. thetaiotaomicron/ovatus 3 64 16 8 64  
4 32 4 0.5 16  
1 8 2 0.5 4  
1 8 1 0.015 4  
7 4 0.5 0.015 1  
B. stercoris 1 16 4 0.015 4  
a ERT, ertapenem; IMI, imipenem; DOR, doripenem.
TABLE 3 In vitro activity of 10 antimicrobial agents against 363 isolates of Bacteroides fragilis grouped by the source of the isolate
Source of isolate and
organism (no. of isolates)
% of isolates susceptible to the following antimicrobial agenta:
AMS PTZ FOX ETP IMI DOR CLI MXF TIG MTZ
Abdomen
B. fragilis (102) 96 99 83 95 99 98 75 92 100 100
Non-B. fragilis species (108) 85 98 65 95 99 99 58 87 100 100
Skin and soft tissues
B. fragilis (35) 100 100 94 100 100 100 65 79 100 100
Non-B. fragilis species (16) 69 94 38 92 100 93 44 81 100 100
Genital tract
B. fragilis (9) 100 100 67 100 100 100 78 89 100 100
Non-B. fragilis species (21) 95 100 76 100 100 100 67 95 100 100
Othersb
B. fragilis (15) 87 93 67 92 93 93 80 100 100 100
Non-B. fragilis species (15) 87 100 33 92 100 92 13 87 100 100
Blood
B. fragilis (30) 96 100 90 95 97 96 66 83 100 100
Non-B. fragilis species (12) 92 100 67 100 100 100 50 75 100 100
a AMS, ampicillin-sulbactam; PTZ, piperacillin-tazobactam; FOX, cefoxitin; ETP, ertapenem; IMI:, imipenem; DOR, doripenem; CLI, clindamycin; MXF, moxifloxacin; TIG,
tigecycline; MTZ, metronidazole.
b The other sources included bones (11 isolates), pericardial fluid (2 isolates), middle ears (6 isolates), lung (1 isolate), head and neck abscesses (3 isolates), hematomas (3 isolates),
and surgical wounds (4 isolates).
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low-level CfiA-producing bacteria, as was already described for
meropenem by Bogaerts et al. (4).
Only a small percentage of B. fragilis strains carrying the cfiA
gene express the protein at a level high enough to classify the strain
as resistant. High-level resistance has been associated with the
presence of an insertion element that may provide an efficient
promoter immediately upstream of the cfiA gene (13, 21, 22). In
our samples, the presence of the cfiA gene was confirmed in 8 out
of 23 isolates of the B. fragilis group displaying resistance or de-
creased susceptibility to carbapenems. The estimated prevalence
of cfiA in clinically imipenem-susceptible B. fragilis isolates (imi-
penem MICs 4 g/ml) was 2.5%, as was described in the liter-
ature (31).
The overall moxifloxacin susceptibility rate remained higher
than that reported by Snydman et al. and Betriu et al. (65.5% and
86.1%, respectively) (2, 28). In our isolates, moxifloxacin resis-
tance was variable among species and ranged from as low as 6.7%
for B. caccae to almost double in B. vulgatus (14.8%) and the less
common species of the group (15.4%). Even at very different lev-
els, the same was previously observed by Snydman et al. (27.4%
and 54.7% for B. fragilis and B. vulgatus, respectively), and Betriu
et al. (9% and 25% for B. fragilis and B. uniformis, respectively). It
is noteworthy that an 8-fold increase in MIC90 values after 10 years
of monitoring was reported. Moxifloxacin activity should be
monitored because of the gradual decrease of MIC values to resis-
tance levels (10, 19, 20, 26).
Previous reports have already shown that resistance to both
clindamycin and cefoxitin makes their empirical use unacceptable
(2, 8, 30). Compared with our last surveys, resistance to clindamy-
cin increased from 16% to 25% within B. fragilis, and, even worse,
from 44 to 48% in non-B. fragilis species (8). It is clear that clin-
damycin should no longer be used without prior susceptibility
testing. For cefoxitin, the range of susceptibility was similar to that
of previous studies (global susceptibility about 60%).
In agreement with previous reports, metronidazole and tigecy-
cline are still the most active agents. In our case, MIC90 values for
tigecycline ranged from 0.125 to 1 g/ml, well below the 4 to 8
g/ml values reported by other authors, and unlike Betriu et al. (3)
and Grisold et al. (11), no resistance of any kind was found. It is
also important to highlight that not a single metronidazole-
resistant isolate was found in Argentina, which is different from
the situation in European countries and the United States (9, 14,
17, 24, 27).
We want to make doctors and scientists aware of the emer-
gence of B. fragilis group isolates resistant to carbapenems and to
piperacillin-tazobactam in Argentina. Among these isolates, the
presence of the cfiA metallo--lactamase gene could be responsi-
ble for the resistance or decreased susceptibility observed in some
isolates of B. fragilis sensu stricto. However, additional studies
should be performed in order to determine the mechanisms in-
volved in the regulation of the expression of the cfiA gene, the
clinical relevance of reduced susceptibility, and the challenge to
discover clues about the mechanisms responsible for the resis-
tance observed in non-B. fragilis isolates.
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